0
Abstract: Poster Presentations |

Adjuvant Therapy of Mediastinitis With IgM-enriched Immunoglobulins (ATMI) - A Multicenter, Randomized Controlled Trial FREE TO VIEW

Günter Marggraf, MD*; Rolf Lefering, PhD; Matthias Thielmann, MD; Wilhelm Struff, MD; Edmund Neugebauer, MD; Heinz Jakob, MD; The ATMI Study Group
Author and Funding Information

Department of Thoracic and Cardiovascular Surgery, West-Germ, Essen, Germany


Chest


Chest. 2004;126(4_MeetingAbstracts):861S. doi:10.1378/chest.126.4_MeetingAbstracts.861S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  Mediastinitis is a rare but severe complication in patients after open heart surgery with cardiopulmonary bypass (CPB). The adjuvant application of IgM-enriched immunoglobulins (Pentaglobin®) was assumed to improve patients outcome and to reduce postoperative complications and infections.

METHODS:  In a prospective, placebo-controlled, double-blind randomized multicenter phase-III study, 125 patients were enrolled between 01/1999 and 04/2002 with postoperative mediastinitis after median sternotomy with CPB and reoperation for wound infection with at least 2 symptoms of systemic inflammation. Pentaglobin® or placebo was administered before wound revision and subsequently as a continuous infusion (5mg/kgBW/d for 5 days IV). Primary endpoint was the sum of daily therapeutic intervention scoring system points for 28 days (cumulative TISS-28). Secondary endpoints were ICU stay, change of MOF score and duration of wound infection.

RESULTS:  One hundred and twenty-five patients were included, 64 received Pentaglobin®, and 61 placebo. Basic data were comparable. Efficacy analysis showed that the median cumulative TISS-28 was lower in the Pentaglobin group by 61 points (189 vs. 250 points, respectively) which on average corresponds to 2 days less of ICU. This difference was not significant (P=0.08; U-test, one-sided). Mean duration of intensive care (7.9±9.1 vs. 9.1±10.1 days), duration of wound infection (10.4±9.7 vs. 12.1±10.9 days) and the MOF score (14±35 vs. 17±37) were reduced as well in the Pentaglobin group. Adverse events were distributed equally. In each group 6 patients (10%) died.

CONCLUSION:  The data demonstrate a clear tendency in favor IgM-enriched immunoglobulins as compared to placebo, although a statistical significance was missed.

DISCLOSURE:  G. Marggraf, None.

Wednesday, October 27, 2004

12:30 PM- 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543